China SFDA, Other Units Begin Two-Week Drug-Safety Crackdown
This article was originally published in PharmAsia News
China's State FDA plans a crackdown on safety issues involved with locally made pharmaceuticals over the next two weeks
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.